| Identification | Back Directory | [Name]
Intermediate | [CAS]
852948-13-1 | [Synonyms]
VK-2809
MB-07811 ( VK-2809)
4-(3-chlorophenyl)-2-((4-(4-hydroxy-3-isopropylbenzyl)-3,5-dimethylphenoxy)methyl)-1,3,2-dioxaphosphinane 2-oxide
(2R,4S)-4-(3-chlorophenyl)-2-((4-(4-hydroxy-3-isopropylbenzyl)-3,5-dimethylphenoxy)methyl)-1,3,2-dioxaphosphinane 2-oxide
4-[[4-[[(2R,4S)-4-(3-Chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-(1-methylethyl)phenol
Phenol, 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-(1-methylethyl)- | [Molecular Formula]
C28H32ClO5P | [MDL Number]
MFCD18827432 | [MOL File]
852948-13-1.mol | [Molecular Weight]
514.98 |
| Chemical Properties | Back Directory | [Melting point ]
77-82 °C | [Boiling point ]
660.6±55.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [solubility ]
Acetonitrile: Soluble
DMSO: Soluble | [form ]
Solid | [pka]
10.31±0.30(Predicted) | [InChIKey]
LGGPZDRLTDGYSQ-WJVKJDHCSA-N | [SMILES]
O1CC[C@@H](C2=CC=CC(Cl)=C2)O[P@@]1(COC1=CC(C)=C(CC2=CC=C(O)C(C(C)C)=C2)C(C)=C1)=O |
| Hazard Information | Back Directory | [Uses]
MB-07811 (VK-2809) is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist[1]. MB-07811 has cholesterol and triglycerides lowering activity[2]. | [in vivo]
MB-07811 (VK-2809) (0.3-30 mg/kg; orally once daily for 14 days) reduces cholesterol and triglycerides in diet-induced obese mice[2]. | Animal Model: | 4-week-old male C57BL/6 mice (diet-induced obese (DIO) mice)[2] | | Dosage: | 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg | | Administration: | Orally once daily; 14 days | | Result: | Reduced total plasma cholesterol, and reduced plasma triglycerides (40%) at the highest doses. |
| [References]
[1] Cable EE, et al. Reduction of hepatic steatosis in rats and mice after treatment with aliver-targeted thyroidhormone receptor agonist. Hepatology. 2009 Feb;49(2):407-17. DOI:10.1002/hep.22572
[2] Erion MD, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15490-5. DOI:10.1073/pnas.0702759104 |
|
|